De Lauretis Angelo, Renzoni Elisabetta A
Interstitial Lung Disease Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK,
Mol Diagn Ther. 2014 Oct;18(5):505-22. doi: 10.1007/s40291-014-0109-0.
Interstitial lung diseases (ILD) are protean conditions with substantial overlap in terms of diagnosis, prognostic evaluation, and management. However, the management of idiopathic pulmonary fibrosis is different from that of more immunologically driven ILD patterns, such as ILD associated with connective tissue diseases. It is important to provide accurate diagnosis and patient selection for prognostication and timely treatment, preferably at baseline. Validated non-invasive biomarkers fulfilling these unmet clinical needs are warranted. Although no ILD biomarker has been adopted in clinical practice so far, advancements in this field have been achieved, especially with the implementation of high-throughput techniques and clinical-laboratory multi-parametric panels. This review focuses on selected validated and/or potentially interesting biomarkers investigated in the peripheral blood and lung tissue of patients with ILD. Current issues and future directions in various aspects of ILD biomarkers research and its clinical application are explored.
间质性肺疾病（ILD）是一类具有多种表现形式的疾病，在诊断、预后评估和管理方面存在大量重叠。然而，特发性肺纤维化的管理与更多由免疫驱动的ILD模式（如与结缔组织病相关的ILD）不同。为了进行预后评估和及时治疗，最好在基线时提供准确的诊断和患者选择，这很重要。需要有经过验证的非侵入性生物标志物来满足这些未满足的临床需求。尽管到目前为止还没有ILD生物标志物被应用于临床实践，但该领域已经取得了进展，特别是随着高通量技术和临床实验室多参数检测组合的实施。本综述重点关注在ILD患者外周血和肺组织中研究的选定的经过验证的和/或潜在有趣的生物标志物。探讨了ILD生物标志物研究及其临床应用各个方面的当前问题和未来方向。
